Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2008-04-30
2009-10-27
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S630000
Reexamination Certificate
active
07608737
ABSTRACT:
This disclosure relates to novel melatonin analogues or naphthyl(ethyl)acetamides, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual melatoninergic agonist and serotoninergic antagonist.
REFERENCES:
patent: 5225442 (1993-07-01), Andrieux et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5318994 (1994-06-01), Andrieux et al.
patent: 5591775 (1997-01-01), Depreux et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6803031 (2004-10-01), Rabinowitz et al.
patent: 7014866 (2006-03-01), Infeld et al.
patent: 2006/0079502 (2006-04-01), Lang
patent: 2006/0094744 (2006-05-01), Maryanoff et al.
patent: 2006/0199805 (2006-09-01), Pyke et al.
patent: 1 564 202 (2005-08-01), None
patent: 1 769 798 (2007-04-01), None
patent: WO 2005/002562 (2005-01-01), None
patent: WO 2005/077887 (2005-08-01), None
patent: WO 2006/086978 (2006-08-01), None
patent: WO 2006/096435 (2006-09-01), None
patent: WO 2006/111653 (2006-10-01), None
patent: WO 2007/028904 (2007-03-01), None
Kushner et al, Can. J. Physiol. Pharmacolo. 77: 79-88, 1999.
Adam et al., “Nouveaux ligands naphtaleniques des recepteurs melatoninergiques,”J. Pharm. Belg.,1992, 47(4):374-380.
Chu et al., “Synthesis of Naphthalenic melatonin receptor cells,”Synth Comm., 2001, 31(4):621-629.
Depreux et al., “Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands,”J. Med. Chem., 1994, 37(20):3231-3239.
Descamps-Francois et al., “Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands,”J. Med. Chem., 2003, 46(7):1127-1129.
Dunetz et al., “Synthesis of highly substituted indolines and indoles via intramolecular [4+2] cycloaddition of ynamides and conjugated enynes,”J. Am. Chem. Soc., 2005, 127(16):5776-5777.
Felix, “Cleavage of protecting groups with boron tibromide,”J. Org. Chem., 1974, 39:1427-1429.
Freireich et al., “Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man,”Cancer Chemother. Rep., 1966, 50:219-244.
Gannes et al., “Natural abundance variations in stable isotopes and their potential uses in animal physiological ecology,”Comp. Biochem. Physiol. Mol. Integr. Physiol., 1998, 119:725-737.
Hayford et al, “Practical synthesis of (Z)-polyaromatic and heteroaromatic vinylacetylenes,”Org. Lett., 2005, 7(13):2671-2673.
Hesse et al, “Natriumtriathoxy-aluminumhydride, ein neues reduktionsmittel in der organischen chemie,”Ann. Chem., 1957, 607:24-35.
Houston, “Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance,”Biochem Pharmacol., 1994, 47:1469-1479.
Houston and Carlile, “Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices,”Drug Metab Rev., 1997, 29:891-922.
“Efficacy, safety and tolerability of agomelatine in the treatment of major depressive disorder,” [online]. Dated Jul. 25, 2008, 4 pages, <http://clinicaltrials.gov/ct/show/NCT00411099>.
Hudlicky,Reductions in Organic Chemistry, 1984, John Wiley and Sons, New York, New York, pp. 173-174.
Iwatsubo et al., “Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data,”Pharmacol Ther., 1997, 73:147-171.
Lave et al., “The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans,”Pharm Res., 1997, 14:152-155.
Loo et al., “A double-blind trial of S-20098 in patients with major depressive or bipolar II disorders: dose-ranging study,”Int. J. Neuropsychopharmacol., 2002, 5(Suppl. 1):Abst P.3.E.033.
MacKenzie et al, “Synthesis of the bacterial coenzyme methoxatin,”Tetrahedron, 1986, 42:3259-3268.
Mewshaw et. al., “ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity,”J. Med. Chem., 2005 48(12):3953-3979.
Nystrom, “Reduction of organic compounds by mixed hydrides I. Nitriles,”J. Am. Chem. Soc., 1955, 77:2544-2545.
Obach, “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes,”Drug Metab. Disp., 1999, 27:1350-1359.
Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 1970, 537.
Suzuki et al, “Synthesis and DNA damaging ability of enediyne-polyamine conjugates,”Tetrahedron Lett., 2004, 45(9):1955-1959.
Vickery et al, “Selective 0-Demethylation of Catechol Ethers, Comparison of Boron Tribromide and Iodotrimethylsilane,”J. Org. Chem., 1979, 44:4444-4446.
Wada et al.,Seikagaku, 1994, 66:15-29.
Xu et al, “Site-specific preparation of 3-fluoro-1-substituted-naphthalenes via a novel base-catalyzed cyclization reaction from (E)-monofluoroenynes,”Org. Lett., 2006, 8(12):2555-2558.
Yous et al., “Novel naphthalenic ligands with high affinity for the melatonin receptor,”J. Med. Chem., 1992, 35(8):1484-1486.
“Refusal CHMP Assessment Report for Valdoxan,”Euro. Medicines Agency, 2006, 1-39.
Burm et al., “Pharmacokinetics of Lidocaine and Bupivacaine and Stable Isotope Labelled Analogues: A Study in Healthy Volunteers,”Bio. & Drug Disp., 1988, 9: 85-95.
Fisher et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-mediated Metabolism,”Curr. Opin. Drug Discov. Dev., 2006, 9(1):101-109.
Foster et al., “Deuterium isotope effects in the metabolism of drugs and xenobiotics,”Adv. In Drug Res., 1985, 14: 2-40.
Helfenbein et al., “Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic,”J. Med. Chem., 2002, 45: 5806-5808.
Kushner et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,”Can. J. Physiol. Pharmacol., 1999, 77:79-88.
Ling et al., “Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis.”Biochem. Biophys. Res. Comm., 1989, 160(2): 844-849.
Ma et al., “Metabolism of Melatonin by Human Cytochromes P450,”Drug. Met. And Disposition, 2005, 33(4): 489-494.
Mamada et al., “Pharmacokinetic Equivalence of Deuterium-Labeled and Unlabeled Phenytoin,”Drug. Met. And Disposition, 1986, 14(4): 509-511.
Obach, “Mechanism of Cytochrome P4503A4- and 2D6-Catalyzed Dehydrogenation of Ezlopitant as Probed with Isotope Effects Using Five Deuterated Analogs,”Drug Met. And Disposition, 2001, 29(12): 1599-1607.
Liu Julie F.
Tung Roger
Concert Pharmaceuticasl Inc.
Fish & Richardson P.C.
Kumar Shailendra
LandOfFree
Naphthyl(ethyl)acetamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthyl(ethyl)acetamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthyl(ethyl)acetamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093692